
Core Insights - Lakeshore Biotech (LSB) experienced a stock price increase of 3.67%, reaching $0.819 per share with a total market capitalization of $33.75 million as of August 16 [1] - As of March 31, 2025, Lakeshore Biotech reported total revenue of 615 million RMB, reflecting a year-on-year growth of 7.24% [1] - The company recorded a net profit attributable to shareholders of -99.98 million RMB, which represents a significant year-on-year increase of 76.93% [1] - Lakeshore Biotech is a Cayman Islands-registered holding company primarily operated by its domestic subsidiary, Beijing Yisheng Biotech Co., Ltd., which focuses on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1]